Literature DB >> 11956106

Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer.

Daqing Wu1, Tonia L Foreman, Christopher W Gregory, Meagan A McJilton, Ginger G Wescott, O Harris Ford, Rudolf F Alvey, James L Mohler, David M Terrian.   

Abstract

Prostatic epithelial cells that are capable of surviving in the absence of androgenic steroids were found to express protein kinase Cepsilon (PKCepsilon), an oncogenic protein capable of promoting autocrine cell-signaling events. Gene transfer experiments demonstrated that PKCepsilon overexpression was sufficient to transform androgen-dependent LNCaP cells into an androgen-independent variant that rapidly initiated tumor growth in vivo in both intact and castrated male nude mice. This transformation was associated with an accelerated rate of androgen-independent LNCaP cell proliferation, resistance to apoptosis, hyperphosphorylation of the mitogen-activated protein kinase extracellular signal-regulated kinase and transcriptional repressor protein retinoblastoma, and increased expression of E2F-1 and other 5'-cap-dependent mRNAs, including the G(1) cyclins, c-myc, and caveolin-1. Coimmunoprecipitation experiments indicated that PKCepsilon was associated with members of the extracellular signal-regulated kinase signaling cascade and the scaffolding protein caveolin-1. Caveolin-1, produced by LNCaP cells overexpressing PKCepsilon, was released into the medium, possibly through a Golgi-independent route, and significant growth inhibition was observed when these cells were cultured in the presence of an anti-caveolin-1 antiserum. Finally, antisense experiments established that endogenous PKCepsilon plays an important role in regulating the growth and survival of androgen-independent prostate cancer cells. This study provides several independent lines of evidence supporting the hypothesis that PKCepsilon expression may be sufficient to maintain prostate cancer growth and survival after androgen ablation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956106

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway.

Authors:  Rachana Garg; Jorge M Blando; Carlos J Perez; Martin C Abba; Fernando Benavides; Marcelo G Kazanietz
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

2.  Imbalance in Protein Thiol Redox Regulation and Cancer-Preventive Efficacy of Selenium.

Authors:  Rayudu Gopalakrishna; Usha Gundimeda; Sarah Zhou; Kristen Zung; Kaitlyn Forell; Arne Holmgren
Journal:  React Oxyg Species (Apex)       Date:  2016-05-25

3.  Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer.

Authors:  Liwei Bao; Michael A Gorin; Manchao Zhang; Alejandra C Ventura; William C Pomerantz; Sofia D Merajver; Theodoros N Teknos; Anna K Mapp; Quintin Pan
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

4.  Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon.

Authors:  Sivalokanathan Sarveswaran; Vijayalakshmi Thamilselvan; Chaya Brodie; Jagadananda Ghosh
Journal:  Biochim Biophys Acta       Date:  2011-07-30

5.  Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.

Authors:  E Masselli; C Carubbi; G Gobbi; P Mirandola; D Galli; S Martini; S Bonomini; M Crugnola; L Craviotto; F Aversa; M Vitale
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

6.  Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.

Authors:  Bilal Bin Hafeez; Joseph W Fischer; Ashok Singh; Weixiong Zhong; Ala Mustafa; Louise Meske; Mohammad Ozair Sheikhani; Ajit Kumar Verma
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-27

Review 7.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

8.  Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model.

Authors:  Bilal Bin Hafeez; Weixiong Zhong; Joseph W Fischer; Ala Mustafa; Xudong Shi; Louise Meske; Hao Hong; Weibo Cai; Thomas Havighurst; Kyungmann Kim; Ajit K Verma
Journal:  Mol Oncol       Date:  2012-12-14       Impact factor: 6.603

9.  Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers.

Authors:  Bilal Bin Hafeez; Weixiong Zhong; Ala Mustafa; Joseph W Fischer; Olya Witkowsky; Ajit K Verma
Journal:  Carcinogenesis       Date:  2012-09-13       Impact factor: 4.944

10.  Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2).

Authors:  M H Aziz; B B Hafeez; J M Sand; D B Pierce; S W Aziz; N E Dreckschmidt; A K Verma
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.